J Clin Neurol.  2012 Mar;8(1):65-68. 10.3988/jcn.2012.8.1.65.

May Long Term Oxcarbazepine Treatment Be Lead to Secondary Hyperparathyroidism?

Affiliations
  • 1Department of Pediatrics, Gulhane Military Medical Faculty, Etlik, Ankara, Turkey. akaraoglu@gata.edu.tr
  • 2Department of Pediatrics, Division of Pediatric Neurology, Gulhane Military Medical Faculty, Etlik, Ankara, Turkey.
  • 3Department of Pediatrics, Division of Pediatric Endocrinology, Gulhane Military Medical Faculty, Etlik, Ankara, Turkey.
  • 4Department of Pharmacology, Gulhane Military Medical Faculty, Etlik, Ankara, Turkey.
  • 5Department of Biochemistry, Gulhane Military Medical Faculty, Etlik, Ankara, Turkey.

Abstract

BACKGROUND
AND PURPOSE: The adverse effects of newer antiepileptic drugs are not well-known. This study assessed the impact of oxcarbazepine (OXC) treatment on bone turnover.
METHODS
Forty-four children with idiopathic focal (and/or secondarily generalized) epilepsy who had been treated with OXC for more than 1 year were compared with 33 healthy, age- and sex-matched children. Serum calcium, phosphorus, alkaline phosphatase, parathyroid hormone, osteocalcin, calcitonin, and 25-hydroxyvitamin D, and bone mineral density were measured to evaluate and compare bone mineralization between the two groups.
RESULTS
The serum levels of calcium, osteocalcin, 25-hydroxyvitamin D, and bone mineral density did not differ significantly between the study and control groups. However, serum levels of parathyroid hormone, alkaline phosphatase, phosphorus, and calcitonin differed significantly between the two groups.
CONCLUSIONS
These findings suggest that OXC treatment leads to secondary hyperparathyroidism with high-turnover bone disease and/or impaired intestinal calcium absorption.

Keyword

oxcarbazepine; bone mineralization; children
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr